Literature DB >> 19325996

Topical application of imiquimod induces alterations in peripheral blood lymphocytes in healthy individuals.

Efi Pasmatzi1, Antigoni Chaidaroglou, Theophilos Sakkis, Alexandra Monastirli, Sophia Georgiou, Alexandros Sagriotis, George Badavanis, Eleftheria Vryzaki, Panagiota Matsouka, Dimitrios Degiannis, Dionysios Tsambaos.   

Abstract

The aim of this study was to determine whether imiquimod, a Toll-like receptor-7/8 agonist, in addition to its well-known topical action on the cutaneous immune response, might also induce alterations in the peripheral blood lymphocytes. A 62.5 mg quantity of imiquimod (5% cream) was applied topically under occlusion once daily every second day for 3 weeks to the skin of 10 healthy volunteers, age range 30-57 years. Ten sex- and age-matched healthy controls applied corresponding quantities of the vehicle under occlusion. Before, and one and 3 weeks after the start of treatment, peripheral blood lymphocyte subpopulations were measured by flow cytometry. Statistically significant alterations in the percentage or absolute numbers of peripheral blood lymphocyte subpopulations were found in the imiquimod-treated group compared with the control group. These alterations indicate for the first time that topical application of imiquimod induces alterations in peripheral blood lymphocyte subsets in healthy individuals, which may be of importance in the immunotherapy of neoplastic and infectious disorders and should be taken into careful consideration in patients who are treated with imiquimod.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325996     DOI: 10.2340/00015555-0597

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

1.  Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.

Authors:  Igor Radanovic; Naomi Klarenbeek; Robert Rissmann; Geert Jan Groeneveld; Emilie M J van Brummelen; Matthijs Moerland; Jacobus J Bosch
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

2.  Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells.

Authors:  Holger Hackstein; Nicole Hagel; Angela Knoche; Sabine Kranz; Jürgen Lohmeyer; Werner von Wulffen; Olivia Kershaw; Achim D Gruber; Gregor Bein; Nelli Baal
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

3.  Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.

Authors:  Tessa van der Kolk; Salma Assil; Rianne Rijneveld; Erica S Klaassen; Gary Feiss; Edwin Florencia; Errol P Prens; Jacobus Burggraaf; Matthijs Moerland; Robert Rissmann; Martijn B A van Doorn
Journal:  Clin Transl Sci       Date:  2018-07-03       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.